Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present CTD Holdings, Inc. (OTC: CTDH).

Full DD Report for CTDH

You must become a subscriber to view this report.


Recent News from (OTC: CTDH)

CTD Holdings Discusses its Phase I Clinical Trial for Intravenous Use of Trappsol® Cyclo(TM) in Niemann-Pick Disease Type C
ALACHUA, Fla., Aug. 30, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, responds today to community queries on the status of its Phase I cli...
Source: GlobeNewswire
Date: August, 30 2018 12:11
CTD Holdings' Trappsol® Cyclo(TM) Featured in Television Program on Niemann-Pick Disease Type C
ALACHUA, Fla., Aug. 23, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, commented on a recent television program featuring Trappsol (R) Cycl...
Source: GlobeNewswire
Date: August, 23 2018 08:00
CTD Holdings Announces Expanded Access Protocol using Intravenous Trappsol® Cyclo(TM) for Alzheimer's Disease
Protocol Available on ClinicalTrials.gov ALACHUA, Fla., Aug. 13, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that th...
Source: GlobeNewswire
Date: August, 13 2018 08:00
CTD to Present at National Niemann-Pick Disease Foundation Annual Conference
Conference brings together families affected by NPC from across the US ALACHUA, Fla., June 27, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB:CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need,...
Source: GlobeNewswire
Date: June, 27 2018 08:00
FDA Authorizes CTD to Proceed with Extension Protocol to US Phase I Trappsol(R) Cyclo(TM) Trial for Niemann-Pick Disease Type C
ALACHUA, FL --(Marketwired - April 30, 2018) - CTD Holdings, Inc. (OTCQB: CTDH) , a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that FDA has authorized its application for "An Open-La...
Source: Marketwired
Date: April, 30 2018 08:00
CTD Holdings Closes $2.00 Million Private Placement
ALACHUA, FL --(Marketwired - April 23, 2018) - CTD Holdings, Inc. (OTCQB: CTDH) , a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that it has closed a private placement of its securities...
Source: Marketwired
Date: April, 23 2018 08:00
CTD Holdings Finalizes Cooperative Agreement for Alzheimer's Disease Research Program
ALACHUA, FL --(Marketwired - April 19, 2018) - CTD Holdings, Inc. (OTCQB: CTDH) , a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has finalized a cooperative research ag...
Source: Marketwired
Date: April, 19 2018 08:00
CTD Holdings Conducts Initial Review of Safety Data for its Phase I and Phase I/II Trials of Trappsol(R) Cyclo(TM) to Treat Niemann-Pick Disease Type C
ALACHUA, FL --(Marketwired - March 29, 2018) - CTD Holdings, Inc. (OTCQB: CTDH) , a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has completed an initial review of safe...
Source: Marketwired
Date: March, 29 2018 13:45
Randall M. Toig, M.D. Joins CTD Holdings Board of Directors
ALACHUA, FL --(Marketwired - March 20, 2018) - CTD Holdings, Inc. (OTCQB: CTDH) , a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that Dr. Randall M. Toig, M.D. of Chicago, IL has joine...
Source: Marketwired
Date: March, 20 2018 08:00
CTD Holdings Announces FDA Authorization to Proceed with Single Patient IND for Use of Trappsol(R) Cyclo(TM) to Treat Alzheimer's Disease
ALACHUA, FL --(Marketwired - March 12, 2018) - CTD Holdings, Inc. (OTCQB: CTDH) , a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that a single patient IND expanded access program using...
Source: Marketwired
Date: March, 12 2018 09:04

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.83250.8150.83250.8151,400
2018-12-130.83250.83250.83250.8325100
2018-12-12N/A0.95N/AN/A0
2018-12-11N/A0.95N/AN/A60
2018-12-100.9990.950.9990.956,950

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-103,8006,95054.6763Short
2018-12-0710012977.5194Short
2018-12-061,0004,35122.9832Cover
2018-12-042,8804,74860.6571Short
2018-12-036,47339,29816.4716Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CTDH.


About CTD Holdings, Inc. (OTC: CTDH)

Logo for CTD Holdings, Inc. (OTC: CTDH)

CTD Holdings, Inc. is a clinical stage biotechnology company that develops cyclodextrin based products for the treatment of diseases with unmet need. The company s Trappsol R Cyclo TM , an orphan drug designated product in the United States and the EU, is used to treat Niemann Pick Type C, a rare and fatal genetic disease. Additional indications for the active ingredient in Trappsol R Cyclo TM are in development. For additional information, visit the company s website: www.ctd holdings.com

 

Contact Information

 

 

Current Management

  • N. Scott Fine / CEO
    • Mr. Fine has been involved in Investment Banking for more than years working on a multitude of debt and equity financings, buy and sell side M amp A, strategic advisory work and corporate restructurings. The majority of his time has been focused on transactions in the healthcare and consumer products area, including time with the Tempo Group of Jakarta, Indonesia when Mr. Fine and his family resided in Jakarta for two years. Mr. Fine was the lead investment banker on the Initial Public Offering for MedDesign Corporation, a specialty medical device company, Keurig Green Mountain Coffee Roasters, and Central European Distribution Corporation, a multibillion dollar alcohol company. He continued his involvement with CEDC serving as a director from until , during which time he led the CEDC Board s successful efforts in to restructure the company through a prepackaged Chapter process whereby CEDC was acquired by the Russian Standard alcohol group. Presently, Mr. Fine serves as Chairman and CEO of CTD Holdings Inc., a Biotechnology/Healthcare Company. He also serves on a number of Boards of Directors including: Better Place, Inc., where he is sole Director Kenon Holdings Ltd, a spinoff from the Israel Corporation Ltd. Global Virus Network and Forward Industries, where he serves as Chairman of the Audit Committee.
  • Jeffrey L. Tate / COO, Chief Scientific Officer
    • Dr. Jeffrey L. Tate has served in senior management of the Company since February , he currently serves as Chief Operation Officer and CSO and is a Director. From January to February , he was president of JJireh Products, Incorporated, a company that develops and markets products manufactured using pulse drying technology. From January to December , Dr. Tate served as a principal of J. Benson Tate Consultants LLC, a management consulting company. From July to January , Dr. Tate served as Vice President of Scientific and Regulatory Affairs of Natural Biologics, LLC, a pharmaceutical company. Dr. Tate received his B.Sc. from the University of Minnesota Department of Botany and his M.Sc. and Ph.D. from the University of Minnesota Graduate School in Management of Technology and Plant Physiology, respectively. Dr. Tate was selected to serve as a member of our Board of Directors because of his position with the Company, experience in manufacturing technology, drug development and formulation, and regulatory affairs.
  • Kevin J Strattan / VP, Fin.
  • N. Scott Fine / Chairman, Audit Committee Member
    • Mr. Fine has been involved in Investment Banking for more than years working on a multitude of debt and equity financings, buy and sell side M amp A, strategic advisory work and corporate restructurings. The majority of his time has been focused on transactions in the healthcare and consumer products area, including time with the Tempo Group of Jakarta, Indonesia when Mr. Fine and his family resided in Jakarta for two years. Mr. Fine was the lead investment banker on the Initial Public Offering for MedDesign Corporation, a specialty medical device company, Keurig Green Mountain Coffee Roasters, and Central European Distribution Corporation, a multibillion dollar alcohol company. He continued his involvement with CEDC serving as a director from until , during which time he led the CEDC Board s successful efforts in to restructure the company through a prepackaged Chapter process whereby CEDC was acquired by the Russian Standard alcohol group. Presently, Mr. Fine serves as Chairman and CEO of CTD Holdings Inc., a Biotechnology/Healthcare Company. He also serves on a number of Boards of Directors including: Better Place, Inc., where he is sole Director Kenon Holdings Ltd, a spinoff from the Israel Corporation Ltd. Global Virus Network and Forward Industries, where he serves as Chairman of the Audit Committee.
  • Joseph J. Farnan / Independent Director
  • F. Patrick Ostronic / Independent Director, Audit Committee Member
    • F. Patrick Ostronic has been a director since April . Mr. Ostronic is an officer of US Pharmacia International, Inc., a subsidiary of USP, and also serves as the Chief Financial Officer of The USP Group. Mr. Ostronic is also a director of Novit US, Inc., the general partner of Novit. Mr. Ostronic s extensive experience in finance and the pharmaceutical industry make him a valuable member of the Board of Directors. Mr. Ostronic was appointed to the Board in connection with a private placement of common stock by the Company in April . Directors, including directors also serving the Company in another capacity and receiving separate compensation therefor, shall be entitled to receive from the Company as compensation for their services as directors such reasonable compensation as the board may from time to time determine, and shall also be entitled to reimbursements for any reasonable expenses incurred in attending meetings of directors.
  • Markus W. Sieger / Independent Director, Compensation Committee Member
    • Markus W. Sieger has been a Director of the Company since February . Mr. Sieger holds a degree in Economics from the University of Applied Sciences for Business and Administration Zurich. He started his career in with Zurich Insurance Group where he specialized in information systems and organizational projects. In , he joined fincoord where he built a track record of negotiating and closing complex merger and acquisition transactions and building up, strategically repositioning and reorganizing companies in both emerging and Western markets. Since , Mr. Sieger is an investor and principal at Sieger amp Sieger Ltd. and Consiglio AG, focusing on strategic advisory mandates and his own investments. He is a director of various companies such as Z.F. Polpharma S.A., Z.T. Kruszwica S.A. and others. He was a director of Central European Distribution Corporation through June . Mr. Sieger s extensive experience in strategic advisory roles and investment opportunities make him a valuable member of our Board of Directors. Mr. Sieger was appointed to the Board of Directors in connection with a private placement of common stock by the Company in February , and has the right to be nominated to our Board or to have a representative nominated to our Board for up to seven years from the date of that offering.
  • Jeffrey L. Tate / Director
    • Dr. Jeffrey L. Tate has served in senior management of the Company since February , he currently serves as Chief Operation Officer and CSO and is a Director. From January to February , he was president of JJireh Products, Incorporated, a company that develops and markets products manufactured using pulse drying technology. From January to December , Dr. Tate served as a principal of J. Benson Tate Consultants LLC, a management consulting company. From July to January , Dr. Tate served as Vice President of Scientific and Regulatory Affairs of Natural Biologics, LLC, a pharmaceutical company. Dr. Tate received his B.Sc. from the University of Minnesota Department of Botany and his M.Sc. and Ph.D. from the University of Minnesota Graduate School in Management of Technology and Plant Physiology, respectively. Dr. Tate was selected to serve as a member of our Board of Directors because of his position with the Company, experience in manufacturing technology, drug development and formulation, and regulatory affairs.

Current Share Structure

  • Market Cap: $22,662,809 - 03/16/2018
  • Authorized: 100,000,000 - 03/01/2018
  • Issue and Outstanding: 73,105,834 - 03/01/2018
  • Float: 16,005,303 - 04/11/2016

 


Recent Filings from (OTC: CTDH)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 24 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 25 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 16 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 16 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: April, 04 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 06 2018

 

 


Daily Technical Chart for (OTC: CTDH)

Daily Technical Chart for (OTC: CTDH)


Stay tuned for daily updates and more on (OTC: CTDH)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CTDH)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CTDH is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CTDH and does not buy, sell, or trade any shares of CTDH. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/